What topics does this cannabis study cover?

This study covers research on: Pain, Endocannabinoid.

How acetaminophen may tap the body’s pain-control system

Q: What did this Review find?

The review proposes that acetaminophen is likely a **prodrug** converted into the bioactive metabolite *AM404* in both central and peripheral nervous tissues.

Q: Where was this research published?

Published in Medical principles and practice : international journal of the Kuwait University, Health Science Centre on August 17, 2026.

Mechanistic Insights into the Analgesic Action of Acetaminophen: Its Bioactive Metabolite Induces Peripheral Analgesia in Addition to Central Analgesia.

Medical principles and practice : international journal of the Kuwait University, Health Science Centre • August 17, 2026 • Review • Related

🤖

AI Summary

This narrative review examines how acetaminophen may relieve pain beyond its relatively weak cyclooxygenase inhibition. The authors conclude that acetaminophen is likely a prodrug—a compound converted in the body into the bioactive metabolite AM404. According to the proposed mechanism, AM404 may be produced in both the central and peripheral nervous systems, suggesting that acetaminophen’s pain relief could involve more than effects in the brain and spinal cord.

AM404 is described as interacting with the cannabinoid type 1 receptor and TRPV1 in the central nervous system, while also potentially reducing pain signaling in peripheral sensory neurons. The review proposes that these peripheral actions may include blocking voltage-gated sodium channels and limiting cyclooxygenase-2-related prostaglandin production. AM404 is related to the body’s endocannabinoid signaling system, but the abstract does not show that acetaminophen produces the same effects as cannabis or THC and CBD. Instead, it presents a mechanistic hypothesis that may help explain acetaminophen’s role in postoperative, inflammatory, and multimodal pain management.

💡 Key Findings

The review proposes that acetaminophen is likely a prodrug converted into the bioactive metabolite AM404 in both central and peripheral nervous tissues.

Moderate

50%

AM404 may contribute to central pain relief by activating the cannabinoid type 1 receptor and TRPV1 channels.

Moderate

50%

The authors hypothesize that peripheral AM404 can suppress pain signaling by inhibiting voltage-gated sodium channels and cyclooxygenase-2-related prostaglandin production.

Moderate

50%

The findings provide a proposed rationale for using acetaminophen in postoperative and inflammatory pain treatment and as part of multimodal analgesia.

Moderate

45%

📄 Original Abstract

The molecular target and detailed mechanism of analgesic acetaminophen are still not fully understood despite being commonly used for many years. Through a literature search, the present study aimed to characterize the cyclooxygenase inhibitory properties of acetaminophen in comparison with non-steroidal anti-inflammatory drugs and to gain novel mechanistic insights into its analgesic action, especially focusing on the peripheral mechanisms. Comparative characterization indicated that acetaminophen is relatively selective for cyclooxygenase-2 but less potent to inhibit cyclooxygenase than non-steroidal anti-inflammatory drugs. This narrative review suggests that acetaminophen is very likely to be a prodrug, which is metabolically converted into bioactive N-arachidonoylphenolamine, AM404, by fatty acid amide hydrolase-mediated conjugation of acetaminophen metabolite 4-aminophenol with arachidonic acid not only in the central nervous system but also in the peripheral nervous system. It is considered that AM404 activates transient receptor potential vanilloid 1 and cannabinoid type 1 receptor distributed in the brain and spinal cord to induce analgesia centrally. In addition, it is speculated that AM404 produced in trigeminal ganglion neurons, dorsal root ganglion neurons, and primary sensory neurons inhibits nociceptive voltage-gated sodium channels through the local anesthetic binding site to suppress pain signaling and inhibits cyclooxygenase-2 to prevent the biosynthesis of prostaglandins responsible for nociception, thereby inducing peripheral analgesia. We propose the mechanistic hypothesis for the analgesic effects of acetaminophen to integrate central and peripheral action of its bioactive entity AM404, which should provide the pharmacological rationale for the use of acetaminophen to relieve postoperative and inflammatory pain and its application to multimodal analgesia.